In This Section
PSMA-Targeted PET Imaging and Radioligand Therapy in the Management of Prostate Cancer: What Urologists Need to Know
Organized by the SNMMI Outreach Domain:
Satellite Breakfast Symposium in conjunction with the American Urological Association Annual Meeting.
Pre-registration is encouraged but not required.
Date: April 30, 2023
Time: 7:30 - 9:30 am CT
Location: Room S100A, McCormick Place Convention Center. Chicago, IL
Fee: Complimentary
REGISTER NOW
This is presented as a Satellite Breakfast Symposium in conjunction with the American Urological Association Annual Meeting.
CE Credit is available for this webinar.
Session Description: Prostate-specific membrane antigen (PSMA) is a type II transmembrane glycoprotein that is highly expressed by prostate cancer cells. In recent years, two small molecules targeting PSMA agents (68Ga-PSMA-11 and 18F-DCFPyL) have been approved by the U.S. Food and Drug Administration for imaging men with localized high-risk or recurrent prostate cancer using positron emission tomography (PET). Additionally, a beta-particle emitting radiotherapeutic agent targeting PSMA (177Lu-PSMA-617) has been approved for the treatment of men with castration-resistant prostate cancer.
In this session, co-presented by a nuclear radiologist and a urologist, we will discuss the basic principles of PET imaging and review the results from key trials of PSMA-targeted PET imaging. We will describe important clinical scenarios in which PSMA-targeted PET imaging is indicated, with a focus on initial cancer staging, biochemical recurrence, management of oligometastatic disease, and selection of candidates for PSMA-targeted radioligand therapy. Additionally, we will review how one can start programs in PSMA-targeted PET imaging and radioligand therapy.
Attendees should be able to return to their practices with the knowledge necessary to start ordering PSMA PET scans and to discuss test results with patients. Additionally, urologists should be able to discuss radioligand therapy with their patients and where this novel therapy fits in the current treatment paradigm for men with castration-resistant prostate cancer. We hope this is a highly interactive session and strongly encourage participation from the audience.
Participants will be eligible to receive one (1.5) AMA-PRA Category 1 Credit and a certificate of participation from the Society of Nuclear Medicine and Molecular Imaging.
Learning Objectives:
- Understand the fundamentals of PET imaging agents and image acquisition, and how those factors play into the choice of radiotracer for imaging of prostate cancer.
- Provide an introduction and understanding of basic PSMA PET image interpretation.
- Recall the key findings regarding sensitivity and specificity of PSMA PET imaging in common clinical scenarios.
- Recognize the appropriate clinical indications for PSMA-targeted PET imaging based on the available medical evidence.
- Understand the role of PSMA-targeted radioligand therapy in the management of men with castration-resistant prostate cancer
Speakers:
Frankis Almaguel, MD, PhD (moderator)
Director, Molecular Imaging and Therapeutics Program
Loma Linda University Cancer Center
Steven Rowe, MD
Associate Professor of Radiology and Urology
Johns Hopkins University School of Medicine
Michael Gorin, MD
Urologist
Icahn School of Medicine at Mount Sinai
This Satellite Breakfast Symposium has been developed by the SNMMI and is supported by an educational grant from Lantheus Medical Imaging.
Pre-registration is encouraged but not required.
CE Accreditation
CME Accreditation – AMA PRA Credits
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
SNMMI has applied for 1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. To receive CE credit, learners must complete the online assessment and evaluation available after the program.